GTSC Podcast

In this podcast, Drs. Linda Martin and Jessica Donington discuss the evolving approach to treating N2 disease in stage 3 lung cancer, emphasizing the shift from therapeutic nihilism to more aggressive surgical strategies. They highlight the success of combining chemotherapy, immunotherapy, and surgery, which has led to improved outcomes, especially in patients with multi-station N2 disease, while noting the importance of rethinking traditional treatment paradigms and focusing on systemic control rather than local clearance alone.

In this episode of the GTSC podcast, Dr. Dennis Wigle (Mayo Clinic) and Dr. Linda Martin (UVA) review the recently published ALINA trial of adjuvant alectinib for resected ALK-positive NSCLC. We also review recently presented lung and esophageal cancer data from ASCO 2024, including ESOPEC, CheckMate 816 and 77T, AEGEAN, and the LU002 trial results for oligometastatic lung cancer. This podcast is sponsored by Genentech.

Dennis Wigle and Linda Martin from Mayo Clinic and University of Virginia, respectively, discuss recent trials from the meeting of the European Society for Medical Oncology (ESMO), particularly highlighting the ALINA trial focusing on adjuvant treatments for resected non small cell lung cancers with impressive differences in outcomes between Alectinib and platinum-based chemotherapy. In addition, they provide a review of multiple perioperative immunotherapy trials from 2023 and share their hopes for the field in 2024. This podcast is sponsored by Genentech.

Drs. Linda Martin (University of Virginia) and Dennis Wigle (Mayo Clinic) review recent clinical trial publications on sublobar resection for early stage lung cancer, and the use of immunotherapy before surgery for later stage (locally advanced) lung cancer. We review the studies involved and provide perspective on the results and what they mean for patient care. This podcast is sponsored by Genentech.